Herpesvirus infection may contribute to Alzheimer’s disease through transposable element activation and neuroinflammation.

ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 ...

Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustain ...

Olpasiran reduces oxidized phospholipids but not inflammation in cardiovascular disease—what does this mean for clinical care ...

A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

Apolipoprotein E4 (apoE4) and female sex are risk factors for developing Alzheimer's disease. It is unclear whether apoE4 contributes to behavioral function at younger ages. Standard ...